Kiniksa Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.81 – an increase of 5.31% over the previous week. Kiniksa Pharmaceuticals employs 315 staff and has a trailing 12-month revenue of around $423.2 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – KNSA.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Kiniksa Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Kiniksa Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kiniksa Pharmaceuticals price performance over time
Historical closes compared with the close of $23.08 from 2025-03-19
1 week (2025-03-13)
4.15%
1 month (2025-02-21)
15.28%
3 months (2024-12-20)
12.09%
6 months (2024-09-20)
-9.98%
1 year (2024-03-20)
16.68%
2 years (2023-03-20)
107.55%
3 years (2022-03-18)
110.20%
5 years (2020-03-20)
76.18%
Kiniksa Pharmaceuticals financials
Revenue TTM
$423.2 million
Gross profit TTM
$234 million
Return on assets TTM
-5.15%
Return on equity TTM
-9.85%
Profit margin
-10.21%
Book value
$6.05
Market Capitalization
$1.6 billion
TTM: trailing 12 months
Kiniksa Pharmaceuticals share dividends
We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.
Have Kiniksa Pharmaceuticals's shares ever split?
Kiniksa Pharmaceuticals's shares were
split on 27 June 2024
.
Kiniksa Pharmaceuticals share price volatility
Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $16.56 up to $28.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is 0.478. This would suggest that Kiniksa Pharmaceuticals's shares are less volatile than average (for this exchange).
Kiniksa Pharmaceuticals overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. .
Frequently asked questions
What percentage of Kiniksa Pharmaceuticals is owned by insiders or institutions? Currently 4.014% of Kiniksa Pharmaceuticals shares are held by insiders and 89.814% by institutions.How many people work for Kiniksa Pharmaceuticals? Latest data suggests 315 work at Kiniksa Pharmaceuticals.When does the fiscal year end for Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals's fiscal year ends in December.Where is Kiniksa Pharmaceuticals based? Kiniksa Pharmaceuticals's address is: 23 Old Bond Street, London, United Kingdom, WIS 4PZWhat is Kiniksa Pharmaceuticals's ISIN number? Kiniksa Pharmaceuticals's international securities identification number is: BMG5269C1010What is Kiniksa Pharmaceuticals's CUSIP number? Kiniksa Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G5269C101
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
